Lobbying disclosures · Lobbying report
TMO: second_quarter 2026 lobbying report
General discussions regarding impact of U.S. federal government workforce changes on industry. General discussions related to clinical trials infrastructure and government labs, and related matters. General discussions regarding diagnostic reimbursement policies. General discussions regarding domestic pharmaceutical manufacturing. H.R. 5269/S. 2761: Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act of 2025 - all provisions of the bill. H.R. 5343/S. 1717: Ensuring Patient Access to Critical Breakthrough Products Act - all provisions of the bill. H.R. 9061:
Follow TMO- Became public
- Jul 13, 2026, 2:43 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 9, 2026, 6:48 PM EST
Why this is connected
Exact legal-name match: THERMO FISHER SCIENTIFIC INC. (https://www.sec.gov/Archives/edgar/data/97745/).
Reported lobbying amounts
Expenses: $280,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/767d51f7-7f17-49a7-9be4-d19c4433eb1f/","filing_uuid":"767d51f7-7f17-49a7-9be4-d19c4433eb1f","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/767d51f7-7f17-49a7-9be4-d19c4433eb1f/print/","filing_document_content_type":"text/html","income":null,"expenses":"280000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Timothy Fenton","dt_posted":"2026-07-13T14:43:56-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"168 Third Avenue","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"Waltham","registrant_state":"MA","registrant_zip":"02454","registrant":{"id":323251,"url":"https://lda.gov/api/v1/registrants/323251/","house_registrant_id":39694,"name":"THERMO FISHER SCIENTIFIC INC.","description":"Scientific equipment, technologies and supplies","address_1":"168 Third Avenue","address_2":null,"address_3":null,"address_4":null,"city":"Waltham","state":"MA","state_display":"Massachusetts","zip":"02454","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JULIA CHEN","contact_telephone":"+1 781-577-8405","dt_updated":"2026-07-10T16:09:57.974170-04:00"},"client":{"id":187246,"url":"https://lda.gov/api/v1/clients/187246/","client_id":12,"name":"THERMO FISHER SCIENTIFIC INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"1899-12-30"},"lobbying_activities":[{"general_issue_code":"LBR","general_issue_code_display":"Labor Issues/Antitrust/Workplace","description":"General discussions regarding impact of U.S. federal government workforce changes on industry.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147741,"prefix":null,"prefix_display":null,"first_name":"KEN","nickname":null,"middle_name":null,"last_name":"MONAHAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151759,"prefix":null,"prefix_display":null,"first_name":"JENNA","nickname":null,"middle_name":null,"last_name":"CARMEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":38,"name":"Labor, Dept of (DOL)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"General discussions related to clinical trials infrastructure and government labs, and related matters. General discussions regarding diagnostic reimbursement policies. General discussions regarding domestic pharmaceutical manufacturing. H.R. 5269/S. 2761: Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act of 2025 - all provisions of the bill. H.R. 5343/S. 1717: Ensuring Patient Access to Critical Breakthrough Products Act - all provisions of the bill. H.R. 9061: Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing (PREEMPT) Act - all provisions of the bill.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":96029,"prefix":null,"prefix_display":null,"first_name":"MOLLY","nickname":null,"middle_name":null,"last_name":"FISHMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147741,"prefix":null,"prefix_display":null,"first_name":"KEN","nickname":null,"middle_name":null,"last_name":"MONAHAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151759,"prefix":null,"prefix_display":null,"first_name":"JENNA","nickname":null,"middle_name":null,"last_name":"CARMEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":65,"name":"General Services Administration (GSA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 5304/S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 - provisions regarding FY26 NIH Funding. General discussions regarding government contract thresholds. Regulation for Federal Financial Assistance (OMB-2026-0034).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147741,"prefix":null,"prefix_display":null,"first_name":"KEN","nickname":null,"middle_name":null,"last_name":"MONAHAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":96029,"prefix":null,"prefix_display":null,"first_name":"MOLLY","nickname":null,"middle_name":null,"last_name":"FISHMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151759,"prefix":null,"prefix_display":null,"first_name":"JENNA","nickname":null,"middle_name":null,"last_name":"CARMEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"HOM","general_issue_code_display":"Homeland Security","description":"Preparedness products and services. General discussions around government contracting opportunities.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":96029,"prefix":null,"prefix_display":null,"first_name":"MOLLY","nickname":null,"middle_name":null,"last_name":"FISHMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147741,"prefix":null,"prefix_display":null,"first_name":"KEN","nickname":null,"middle_name":null,"last_name":"MONAHAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151759,"prefix":null,"prefix_display":null,"first_name":"JENNA","nickname":null,"middle_name":null,"last_name":"CARMEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"LAW","general_issue_code_display":"Law Enforcement/Crime/Criminal Justice","description":"POWER Act; all provisions of the bill.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147741,"prefix":null,"prefix_display":null,"first_name":"KEN","nickname":null,"middle_name":null,"last_name":"MONAHAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":96029,"prefix":null,"prefix_display":null,"first_name":"MOLLY","nickname":null,"middle_name":null,"last_name":"FISHMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151759,"prefix":null,"prefix_display":null,"first_name":"JENNA","nickname":null,"middle_name":null,"last_name":"CARMEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":201,"name":"Homeland Security, Dept of (DHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"General discussions regarding trade and tariffs, including with respect to markets including China. United States-Mexico-Canada Agreement.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147741,"prefix":null,"prefix_display":null,"first_name":"KEN","nickname":null,"middle_name":null,"last_name":"MONAHAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":96029,"prefix":null,"prefix_display":null,"first_name":"MOLLY","nickname":null,"middle_name":null,"last_name":"FISHMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151759,"prefix":null,"prefix_display":null,"first_name":"JENNA","nickname":null,"middle_name":null,"last_name":"CARMEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"},{"id":22,"name":"U.S. Trade Representative (USTR)"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"General discussions regarding the expiration of key provisions of the 2017 Tax Cuts and Jobs Act, and other tax-related priorities.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147741,"prefix":null,"prefix_display":null,"first_name":"KEN","nickname":null,"middle_name":null,"last_name":"MONAHAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":96029,"prefix":null,"prefix_display":null,"first_name":"MOLLY","nickname":null,"middle_name":null,"last_name":"FISHMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Price change after we could observe it
-0.07% TMO
Adjusted closing prices from Nov 10, 2026 to Nov 11, 2026. SPY changed 1.32% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.
Congressional trading in TMO
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
Sold Thermo Fisher Scientific TMO
$15K–$50K · Traded Oct 13, 2026 · disclosed Nov 5, 2026 · Dependent
Traded 8 days before earnings - Aug 7, 2026$1K–$15K
Rep. Michael A. Rulli (R-OH-6)
Sold Thermo Fisher Scientific TMO
$1K–$15K · Traded Dec 12, 2024 · disclosed Aug 7, 2026 · filed 603 days later
- Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
Bought Thermo Fisher Scientific TMO
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jul 17, 2026$1K–$15K
Rep. Dan Newhouse (R-WA-4)
Sold Thermo Fisher Scientific TMO
$1K–$15K · Traded Jul 10, 2026 · disclosed Jul 17, 2026 · Spouse
Traded 13 days before earnings - May 15, 2026$1K–$15K
Rep. Dwight Evans (D-PA-3)
Sold (partial) Thermo Fisher Scientific TMO
$1K–$15K · Traded May 7, 2026 · disclosed May 15, 2026
- May 11, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
Bought Thermo Fisher Scientific TMO
$15K–$50K · Traded Apr 13, 2026 · disclosed May 11, 2026 · Spouse
- Feb 6, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
Sold Thermo Fisher Scientific TMO
$15K–$50K · Traded Jan 29, 2026 · disclosed Feb 6, 2026 · Spouse
- Jan 13, 2026$1K–$15K
Rep. Julia Letlow (R-LA-5)
Bought Thermo Fisher Scientific TMO
$1K–$15K · Traded Jul 25, 2025 · disclosed Jan 13, 2026 · filed 172 days later
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.